RCOphth NOD AMD Audit Year 4: Neovascular AMD Treatment Outcomes 2023-2024

The 2023-2024 NHS year (01/04/2023 to 31/03/2024) comprises the second prospective year of the National Age-related Macular Degeneration Audit. It contains results for eyes starting treatment for neovascular AMD during that period, with data on their first year of treatment and one-year follow-up outcomes. The data was collected from 75 participating clinical centers across the UK as part of routine care by the Royal College of Ophthalmologists.

Use Cases

• Benchmarking clinical center performance based on treatment outcomes reported in the audit.
• Analyzing treatment initiation trends for neovascular AMD across different UK regions and trust types.
• Studying one-year follow-up results for patients completing a full treatment cycle.
• Investigating geographic or organizational variations in AMD care delivery within the NHS.

Strengths

• Data collected from 75 participating clinical centers across the UK, providing a multi-center perspective.
• Includes results for both the first year of treatment and one-year follow-up outcomes for a defined cohort.
• Results are aggregated from contributing English and Scottish NHS Trusts, Northern Irish Health and Social Care Trusts, Welsh Health Boards, and Independent Sector Treatment Centres.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Results are not produced for centers with fewer than 25 eyes with relevant data, which may exclude smaller sites.

Provenance

Source

Royal College of Ophthalmologists

Collection Method

Collected as part of routine clinical care on electronic medical record systems.

Time Range

01/04/2023 to 31/03/2024

Freshness

Last updated 2026-06-09 13:20:38.670021; freshness should be verified.

Geography

United Kingdom (England, Scotland, Wales, Northern Ireland), Guernsey